34 results on '"Javier Menárguez"'
Search Results
2. Clinical Utility of the Detection of the Loss of the Mismatched HLA in Relapsed Hematological Patients After Haploidentical Stem Cell Transplantation With High-Dose Cyclophosphamide
- Author
-
Paula Muñiz, Mi Kwon, Diego Carbonell, María Chicano, Rebeca Bailén, Gillen Oarbeascoa, Julia Suárez-González, Cristina Andrés-Zayas, Javier Menárguez, Nieves Dorado, Ignacio Gómez-Centurión, Javier Anguita, José Luis Díez-Martín, Carolina Martínez-Laperche, and Ismael Buño
- Subjects
HLA-loss ,immune evasion ,post-transplantation relapse ,haploidentical stem cell transplantation ,cyclophosphamide ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Haploidentical hematopoietic stem cell transplantation (Haplo-HSCT) with high-dose cyclophosphamide (PTCy) has resulted in a low incidence of graft-vs.-host disease (GVHD), graft failure, and non-relapse mortality. However, post-transplantation relapse remains a common cause of treatment failure in high-risk patients. Unraveling the mechanisms of relapse is therefore crucial for designing effective relapse treatment strategies. One of these mechanisms is the loss of the mismatched HLA on the recipient's leukemic cells. To study the incidence and clinical relevance of this phenomenon, we analyzed 181 patients treated with Haplo-HSCT with PTCy (2007–2019), of which 37 relapsed patients after transplantation. According to the kit employed for HLA-loss analysis, among 22 relapsed patients, we identified HLA loss at relapse in 6 of the 22 patients (27%) studied. Based on the results obtained, the genomic loss of HLA was more common in females than males (66 vs. 33%) and HLA-loss relapses occurred later than classical relapses (345 vs. 166 days). Moreover, the patients with HLA-loss had a greater presence of active disease at the time of transplantation and had undergone a larger number of treatment lines than the group with classical relapses (66 vs. 43% and 66 vs. 18%, respectively). Four of these relapses were studied retrospectively, while two were studied prospectively, the results of which could be considered for patient management. Additionally, two relapsed patients analyzed retrospectively had myeloid neoplasms. One patient had not undergone any treatment, and three had undergone donor lymphocyte infusions (DLIs) and chemotherapy. All presented severe GVHD and disease progression. In contrast, the two patients studied prospectively had a lymphoid neoplasm and were not treated with DLIs. One of them was treated with chemotherapy but died from disease progression, and the other patient underwent a second Haplo-HSCT from a different donor and is still alive. We can conclude that the detection of HLA-loss at the onset of relapse after Haplo-HSCT with PTCy could help in clinical practice to select appropriate rescue treatment, thereby avoiding the use of DLIs or a second transplantation from the same donor.
- Published
- 2021
- Full Text
- View/download PDF
3. Lymphoplasmacytic lymphoma associated with diffuse large B-cell lymphoma: Progression or divergent evolution?
- Author
-
Macarena Boiza-Sánchez, Rebeca Manso, Olga Balagué, Cristina Chamizo, Elham Askari, Rocío Nieves Salgado, Carlos Blas-López, Elena Aguirregoicoa-García, Javier Menárguez, Carlos Santonja, Magdalena Adrados, Miguel Ángel Limeres-González, Miguel Ángel Piris, and Socorro María Rodríguez-Pinilla
- Subjects
Medicine ,Science - Abstract
AimLymphoplasmacytic lymphoma (LPL) is an indolent mature B-cell-neoplasm with involvement of the bone marrow. At least 90% of LPLs carry MYD88-L265P mutation and some of them (~10%) transform into diffuse large B-cell-lymphoma (DLBCL).Material and methodsOver the past 15 years we have collected 7 cases where the both LPL and DLBCL were diagnosed in the same patient. Clinical records, analytical data and histopathological specimens were reviewed. FISH studies on paraffin-embedded tissue for MYC, BCL2 and BCL6 genes were performed, as well as MYD88-L265P mutation and IGH rearrangement analysis by PCR. A mutational study was done by massive next generation sequencing (NGS).ResultsThere were 4 women and 3 men between 36-91 years of age. Diagnoses were made simultaneously in 4 patients. In two cases the LPL appeared before the DLBCL and in the remaining case the high-grade component was discovered 5 years before the LPL. In 6 cases both samples shared the MYD88-L265P mutation. IGH rearrangement analysis showed overlapping features in two of 6 cases tested. Mutational study was evaluable in three cases for both samples showing shared and divergent mutations.ConclusionsThese data suggest different mechanisms of DLBCL development in LPL patients.
- Published
- 2020
- Full Text
- View/download PDF
4. Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphoma.
- Author
-
Julia González-Rincón, Miriam Méndez, Sagrario Gómez, Juan F García, Paloma Martín, Carmen Bellas, Lucía Pedrosa, Socorro M Rodríguez-Pinilla, Francisca I Camacho, Cristina Quero, David Pérez-Callejo, Antonio Rueda, Marta Llanos, José Gómez-Codina, Miguel A Piris, Santiago Montes-Moreno, Carmen Bárcena, Delvys Rodríguez-Abreu, Javier Menárguez, Luis de la Cruz-Merino, Silvia Monsalvo, Consuelo Parejo, Ana Royuela, Ivo Kwee, Luciano Cascione, Alberto Arribas, Francesco Bertoni, Manuela Mollejo, Mariano Provencio, and Margarita Sánchez-Beato
- Subjects
Medicine ,Science - Abstract
Follicular lymphoma (FL) is an indolent but largely incurable disease. Some patients suffer histological transformation to a more aggressive subtype with poorer prognosis. This study aimed to improve our understanding of the genetics underlying FL histological transformation, and to identify genetic drivers or promoters of the transformation by elucidating the differences between FL samples from patients who did and did not transform. We conducted targeted massive parallel sequencing of 22 pre-transformed FL/transformed diffuse large B-cell lymphoma pairs and 20 diagnostic samples from non-transformed FL patients. Additionally, 22 matched samples from 11 transformed FL patients (pre-transformed FL and diffuse large B-cell lymphoma) and 9 non-transformed FLs were studied for copy number variation using SNP arrays. We identified recurrently mutated genes that were enriched at transformation, most notably LRP1B, GNA13 and POU2AF1, which have roles in B-cell differentiation, GC architecture and migration. Mutations in POU2AF1 might be associated with lower levels of expression, were more frequent in transformed FLs, and seemed to be specific to transformed- compared with de novo-diffuse large B-cell lymphomas. Pre-transformed FLs carried more mutations per sample and had greater subclonal heterogeneity than non-transformed FLs. Finally, we identified four mutated genes in FL samples that differed between patients who did and did not transform: NOTCH2, DTX1, UBE2A and HIST1H1E. The presence of mutations in these genes was associated with shorter time to transformation when mutated in the FL biopsies. This information might be useful for identifying patients at higher risk of transformation.
- Published
- 2019
- Full Text
- View/download PDF
5. C-MYC is related to GATA3 expression and associated with poor prognosis in nodal peripheral T-cell lymphomas
- Author
-
Rebeca Manso, Carmen Bellas, Paloma Martín-Acosta, Manuela Mollejo, Javier Menárguez, Federico Rojo, Pilar Llamas, Miguel A. Piris, and Socorro M. Rodríguez-Pinilla
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Published
- 2016
- Full Text
- View/download PDF
6. Supplementary Figure 8 from E2F1 Expression Is Deregulated and Plays an Oncogenic Role in Sporadic Burkitt's Lymphoma
- Author
-
Miguel R. Campanero, Miguel A. Piris, Erik K. Flemington, Javier Menárguez, María-Jesús Artiga, Daniel Martín-Pérez, Patricia Rebollo, María Rodríguez-Martínez, and Irene Molina-Privado
- Abstract
Supplementary Figure 8 from E2F1 Expression Is Deregulated and Plays an Oncogenic Role in Sporadic Burkitt's Lymphoma
- Published
- 2023
7. Data from E2F1 Expression Is Deregulated and Plays an Oncogenic Role in Sporadic Burkitt's Lymphoma
- Author
-
Miguel R. Campanero, Miguel A. Piris, Erik K. Flemington, Javier Menárguez, María-Jesús Artiga, Daniel Martín-Pérez, Patricia Rebollo, María Rodríguez-Martínez, and Irene Molina-Privado
- Abstract
Current treatments of sporadic Burkitt's lymphoma (sBL) are associated with severe toxicities. A better understanding of sBL formation would facilitate development of less toxic therapies. The etiology of sBL remains, however, largely unknown, C-MYC up-regulation being the only lesion known to occur in all sBL cases. Several studies examining the role of C-MYC in the pathogenesis of BL have concluded that C-MYC translocation is not the only critical event and that additional unidentified factors are expected to be involved in the formation of this tumor. We herein report that a gene distinct from C-MYC, E2F1, is involved in the formation of all or most sBL tumors. We found that E2F1 is highly expressed in Burkitt's lymphoma cell lines and sBL lymphoma specimens. Our data indicate that its elevated expression is not merely the consequence of the presence of more cycling cells in this tumor relative to other cell lines or to other neoplasias. In fact, we show that reduction of its expression in sBL cells inhibits tumor formation and decreases their proliferation rate. We also provide data suggesting that E2F1 collaborates with C-MYC in sBL formation. E2F1 expression down-regulation did not affect, however, the proliferation of human primary diploid fibroblasts. Because E2F1 is not needed for cell proliferation of normal cells, our results reveal E2F1 as a promising therapeutic target for sBL. [Cancer Res 2009;69(9):4052–8]
- Published
- 2023
8. Supplementary Figure 7 from E2F1 Expression Is Deregulated and Plays an Oncogenic Role in Sporadic Burkitt's Lymphoma
- Author
-
Miguel R. Campanero, Miguel A. Piris, Erik K. Flemington, Javier Menárguez, María-Jesús Artiga, Daniel Martín-Pérez, Patricia Rebollo, María Rodríguez-Martínez, and Irene Molina-Privado
- Abstract
Supplementary Figure 7 from E2F1 Expression Is Deregulated and Plays an Oncogenic Role in Sporadic Burkitt's Lymphoma
- Published
- 2023
9. Supplementary Figure 6 from E2F1 Expression Is Deregulated and Plays an Oncogenic Role in Sporadic Burkitt's Lymphoma
- Author
-
Miguel R. Campanero, Miguel A. Piris, Erik K. Flemington, Javier Menárguez, María-Jesús Artiga, Daniel Martín-Pérez, Patricia Rebollo, María Rodríguez-Martínez, and Irene Molina-Privado
- Abstract
Supplementary Figure 6 from E2F1 Expression Is Deregulated and Plays an Oncogenic Role in Sporadic Burkitt's Lymphoma
- Published
- 2023
10. Supplementary Figure 9 from E2F1 Expression Is Deregulated and Plays an Oncogenic Role in Sporadic Burkitt's Lymphoma
- Author
-
Miguel R. Campanero, Miguel A. Piris, Erik K. Flemington, Javier Menárguez, María-Jesús Artiga, Daniel Martín-Pérez, Patricia Rebollo, María Rodríguez-Martínez, and Irene Molina-Privado
- Abstract
Supplementary Figure 9 from E2F1 Expression Is Deregulated and Plays an Oncogenic Role in Sporadic Burkitt's Lymphoma
- Published
- 2023
11. Supplementary Figures 1-5 from E2F1 Expression Is Deregulated and Plays an Oncogenic Role in Sporadic Burkitt's Lymphoma
- Author
-
Miguel R. Campanero, Miguel A. Piris, Erik K. Flemington, Javier Menárguez, María-Jesús Artiga, Daniel Martín-Pérez, Patricia Rebollo, María Rodríguez-Martínez, and Irene Molina-Privado
- Abstract
Supplementary Figures 1-5 from E2F1 Expression Is Deregulated and Plays an Oncogenic Role in Sporadic Burkitt's Lymphoma
- Published
- 2023
12. Incorporation of next-generation sequencing in clinical practice using solid and liquid biopsy for patients with non-Hodgkin's lymphoma
- Author
-
Mariana Bastos-Oreiro, José Luis Díez-Martín, Solsiré Moreno, Francisco Javier Diaz-Crespo, Cristina Andrés-Zayas, Julia Suárez-González, Diego Carbonell, Laura Sanz, Ismael Buño, Javier Menárguez, Carolina Martínez-Laperche, María Chicano, Paula Muñiz, and Natalia Carolina Carrión
- Subjects
Pathology ,medicine.medical_specialty ,Somatic cell ,Science ,DNA Mutational Analysis ,Follicular lymphoma ,DNA sequencing ,Article ,Predictive Value of Tests ,hemic and lymphatic diseases ,Biopsy ,medicine ,Biomarkers, Tumor ,Humans ,Liquid biopsy ,Lymphoma, Follicular ,Cancer genetics ,Multidisciplinary ,medicine.diagnostic_test ,business.industry ,B-cell lymphoma ,Liquid Biopsy ,High-Throughput Nucleotide Sequencing ,Reproducibility of Results ,medicine.disease ,Lymphoma ,Non-Hodgkin's lymphoma ,Clinical Practice ,Mutation ,Medicine ,Lymphoma, Large B-Cell, Diffuse ,business - Abstract
Although next-generation sequencing (NGS) data on lymphomas require further validation before being implemented in daily practice, the clinical application of NGS can be considered right around the corner. The aim of our study was to validate an NGS lymphoid panel for tissue and liquid biopsy with the most common types of non-Hodgkin’s lymphoma [follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL)]. In this series, 372 somatic alterations were detected in 93.6% (44/47) of the patients through tissue biopsy. In FL, we identified 93 somatic alterations, with a median of 7.4 mutations per sample. In DLBCL, we detected 279 somatic variants with a median of 8.6 mutations (range 0–35). In 92% (24/26) of the cases, we were able to detect some variant in the circulating tumor DNA. We detected a total of 386 variants; 63.7% were detected in both types of samples, 13.2% were detected only in the circulating tumor DNA, and 23% were detected only in the tissue biopsy. We found a correlation between the number of circulating tumor DNA mutations, advanced stage, and bulky disease. The genetic alterations detected in this panel were consistent with those previously described at diagnosis. The liquid biopsy sample is therefore a complementary tool that can provide new genetic information, even in cases where a solid biopsy cannot be performed or an insufficient sample was obtained. In summary, we describe and analyze in this study the findings and difficulties encountered when incorporating liquid biopsy into clinical practice in non-Hodgkin’s lymphoma at diagnosis.
- Published
- 2021
13. ANALYSIS OF EZH2 MUTATIONS IN SOLID AND LIQUID BIOPSY AND ITS ROLE AS PREDICTIVE BIOMARKER FOR CHEMOTHERAPY IN PATIENTS WITH FOLLICULAR LYMPHOMA
- Author
-
María Chicano, F. Díaz Crespo, Javier Menárguez, Carolina Martínez-Laperche, Mi Kwon, M. Bastos Oreiro, Ismael Buño, Paula Muñiz, Diego Carbonell, J. Suárez-González, L. Sanz-Villanueva, R. M. Martín Rojas, and J. L. Diez Martín
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Chemotherapy ,business.industry ,medicine.medical_treatment ,EZH2 ,Follicular lymphoma ,Hematology ,General Medicine ,medicine.disease ,Internal medicine ,medicine ,In patient ,Liquid biopsy ,business ,Predictive biomarker - Published
- 2021
14. RELAPSE CHARACTERIZATION IN DIFFUSE LARGE B CELL LYMPHOMA PATIENTS UNDERGOING COMMERCIAL CAR‐T CELL THERAPY: EXPERIENCE FROM A SINGLE CENTRE
- Author
-
A. Pérez Corral, P. Silva, Rebeca Bailén, Ismael Buño, I. Gómez-Fernández, Nieves Dorado, Silvia Monsalvo, Javier Menárguez, F. Díaz Crespo, J. Anguita Velasco, Carolina Martínez-Laperche, Mariana Bastos-Oreiro, Cristina Muñoz, José Luis Díez-Martín, S. Sabell, Diego Carbonell, Mi Kwon, and Gillen Oarbeascoa
- Subjects
Cancer Research ,Single centre ,Oncology ,business.industry ,medicine ,Cancer research ,CAR T-cell therapy ,Hematology ,General Medicine ,medicine.disease ,business ,Diffuse large B-cell lymphoma - Published
- 2021
15. Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma
- Author
-
Michael Grau, Kirsty Wienand, Pia Veratti, Gustavo Tapia, Tabea Erdmann, Eva González-Barca, Falko Fend, Jan-Niklas Heming, Björn Chapuy, Irina Bonzheim, Sophia Ehrenfeld, Alexandar Tzankov, Javier Menárguez, Mathias Lutz, Philip Sander, Matthew R. Wilson, José-Tomás Navarro, Julia Richter, Wolfram Klapper, Stefan Dirnhofer, Cornelius Miething, Pau Abrisqueta, Andreas Rosenwald, Fina Climent, Ioannis Anagnostopoulos, Mario Lamping, Wendan Xu, Annette M. Staiger, Georg Lenz, Myroslav Zapukhlyak, Philipp Berning, Vanessa Borgmann, Wolfgang Hartmann, Peter Lenz, Teresa Aldamiz, Fabian Frontzek, German Ott, Maria Joao Baptista, Josep Castellví, Antonio Salar, Jose Luis Mate, Heike Horn, John R. Goodlad, Ramona Wullenkord, Institut Català de la Salut, [Frontzek F, Zapukhlyak M, Xu W] Department of Medicine A, Department of Hematology, Oncology and Pneumology, University Hospital Münster, Münster, Germany. [Staiger AM] Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart and University of Tuebingen, Tübingen, Germany. Department of Clinical Pathology, Robert Bosch Hospital, Stuttgart, Germany. [Bonzheim I, Borgmann V] Institute of Pathology and Neuropathology, Eberhard Karls University of TübingenComprehensive Cancer Center, University Hospital Tübingen, Tübingen, Germany. [Castellvi J] Servei de Patologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Abrisqueta P] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
Male ,Limfomes ,Investigative Techniques::Genetic Techniques::Sequence Analysis::Sequence Analysis, DNA::Whole Genome Sequencing::Whole Exome Sequencing [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,medicine.medical_treatment ,Gene Dosage ,General Physics and Astronomy ,Interferó ,Aggressive lymphoma ,Disease ,Translocation, Genetic ,Whole Exome Sequencing ,Cohort Studies ,hemic and lymphatic diseases ,MCL1 ,Molecular Targeted Therapy ,B-cell lymphoma ,Càncer ,Cancer genetics ,Sistema limfàtic - Càncer - Mortalitat ,Exome sequencing ,Otros calificadores::/terapia [Otros calificadores] ,Cancer ,Aged, 80 and over ,Multidisciplinary ,Immunosuppression ,Neoplasms::Neoplasms by Histologic Type::Lymphoma::Lymphoma, Non-Hodgkin::Lymphoma, B-Cell::Lymphoma, Large B-Cell, Diffuse::Plasmablastic Lymphoma [DISEASES] ,Middle Aged ,STAT Transcription Factors ,Interferon Regulatory Factors ,Plasmablastic Lymphoma ,Female ,técnicas de investigación::técnicas genéticas::análisis de secuencias::análisis de secuencias de ADN::secuenciación del genoma completo::secuenciación del exoma completo [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,Adult ,neoplasias::neoplasias por tipo histológico::linfoma::linfoma no Hodgkin::linfoma de células B::linfoma de células B grandes difuso::linfoma plasmablástico [ENFERMEDADES] ,Adolescent ,Science ,Cèl·lules B ,Mapatge cromosòmic humà ,Cèl·lules B - Tumors - Tractament ,General Biochemistry, Genetics and Molecular Biology ,Article ,Young Adult ,Exome Sequencing ,medicine ,Mortalitat ,Humans ,Human gene mapping ,Seqüència de nucleòtids ,Aged ,Janus Kinases ,B cells ,business.industry ,Gene Expression Profiling ,Gene Amplification ,General Chemistry ,Other subheadings::/therapy [Other subheadings] ,medicine.disease ,Cancer research ,business ,Plasmablastic lymphoma ,Genètica ,IRF4 - Abstract
Plasmablastic lymphoma (PBL) represents a rare and aggressive lymphoma subtype frequently associated with immunosuppression. Clinically, patients with PBL are characterized by poor outcome. The current understanding of the molecular pathogenesis is limited. A hallmark of PBL represents its plasmacytic differentiation with loss of B-cell markers and, in 60% of cases, its association with Epstein-Barr virus (EBV). Roughly 50% of PBLs harbor a MYC translocation. Here, we provide a comprehensive integrated genomic analysis using whole exome sequencing (WES) and genome-wide copy number determination in a large cohort of 96 primary PBL samples. We identify alterations activating the RAS-RAF, JAK-STAT, and NOTCH pathways as well as frequent high-level amplifications in MCL1 and IRF4. The functional impact of these alterations is assessed using an unbiased shRNA screen in a PBL model. These analyses identify the IRF4 and JAK-STAT pathways as promising molecular targets to improve outcome of PBL patients., Plasmablastic lymphoma (PBL) is an aggressive lymphoma subtype characterized by poor prognosis but the molecular knowledge of the disease is limited. Here, the authors perform whole exome sequencing and copy number determination of primary samples highlighting IRF4 and JAK-STAT pathways as therapeutic targets for PBL.
- Published
- 2021
16. Cell-Free DNA Dynamic Concentration, CRP and LDH Pre-Infusion Are Predictors of Early Progression after CAR T-Cell Therapy in DLBCL Patients
- Author
-
Diego Carbonell, Ismael Buño, Javier Menárguez, Paula Muñiz, Carolina Martínez-Laperche, Francisco Diaz Crespo, Gillen Oarbeascoa, José Luis Díez-Martín, Mi Kwon, María Chicano Lavilla, Rebeca Bailén, Mariana Bastos Oreiro, Laura Sanz-Villanueva, and Isabel Gomez
- Subjects
Cell-free fetal DNA ,business.industry ,Immunology ,Cancer research ,CAR T-cell therapy ,Medicine ,Cell Biology ,Hematology ,business ,Biochemistry - Abstract
Introduction: Chimeric antigen receptor (CAR) T-Cell therapy is approved for relapse/refractory diffuse large B cell lymphoma (DLBCL) patients after two lines of therapy. Although it is an effective treatment, approximately 20-30% of patients have an early relapse. In this context, biomarkers that helps to identify those patients who will be refractory to this therapy are relevant. Cell-free DNA (cfDNA) has emerged as a new tool for non-invasive monitoring of patients with lymphoma, therefore the aim of this study was to evaluate dynamic cfDNA concentration in addition to other biomarkers (LDH, CRP, ferritin) before CAR T-cell infusion to detect early progressors. Methods: We selected 44 r/r DLBCL patients treated with CAR T-cell in our centre. Plasma samples were collected pre-apheresis (PA) and pre-infusion (PI)(∆cfDNA). Other biomarkers (LDH, CRP, Ferritin) were studied PA, pre-lymphodepletion (PL) and PI, tumour volume metabolic (TMV) are also studied. CfDNA were obtained from plasma using QIAamp® Circulating Nucleic Acid (Qiagen) and quantified by QuantiFluor dsDNA System (Promega). The Mann-Whitney test was used to compare differences between two independent quantitative variables . ROC analysis was conducted to determine the cut-off value of biomarkers. Cumulative incidence of progression (1 and 3 months) was calculated from the date of CAR T-cell infusion. Data analysis was performed using Stata. Results: Cumulative incidence of relapse at 1 month and 3 months was 20% and 30% respectively. The correlation between the progression (1 month, 3 months) and the different biomarkers is shown in Table 1. The CRP PL, CRP PI, LDH PI and ∆cfDNA (PI-PA, median time 41.5 days [range:31-107]) was correlated with early progression (1 month). No differences were found with progression at 3 months. The different cut-off for the biomarkers selected was 9 ng/mL for ∆cfDNA, 225 U/L for LDH and 1.35 mg/dL for CRP. Cumulative incidence of progression at 1 month was calculated for these biomarkers (figure 1): ∆cfDNA, HR: 4.3 (1.05-17), p=0.042; CRP PL: HR: 6.9 (1.5-31.1), p=0.012; CRP PI, HR: 11.2 (1.5-83), p=0.019 and LDH PI, HR: 3.4 (1-17) p=0.11. It should be noted that 83.3% (10/12) of the patients who progressed during the first month had at least one of the above variables. Conclusions: Our results highlight that increase in cfDNA higher than 9 ng/mL, CRP PL and PI >1.35 mg/dL and LDH PI > 225 U/L before CAR T-cell therapy may detect early progressors within the first month after treatment. Therefore, ∆cfDNA, CRP and LDH could be useful to identify patients who highly probable will not benefit from the CAR T infusion, in which another prior strategy could be considered in an attempt to control the disease. These results need to be confirmed with a larger cohort. Figure 1 Figure 1. Disclosures Bailén: Pfizer: Honoraria; Kite-Gilead: Honoraria; Gilead: Honoraria. Kwon: Gilead: Honoraria.
- Published
- 2021
17. Mutations in the JAK/STAT pathway genes and activation of the pathway, a relevant finding in nodal Peripheral T-cell lymphoma
- Author
-
Miguel A. Piris, Socorro María Rodríguez-Pinilla, Federico Rojo, Rebeca Manso, Manuela Mollejo, Sagrario Gómez, Margarita Sánchez-Beato, Javier Menárguez, Mónica García-Cosío, and Julia González-Rincón
- Subjects
Mutation ,Lymphoma, T-Cell, Peripheral ,JAK-STAT signaling pathway ,Hematology ,Biology ,medicine.disease_cause ,medicine.disease ,Peripheral T-cell lymphoma ,Neoplasm Proteins ,STAT Transcription Factors ,03 medical and health sciences ,0302 clinical medicine ,030220 oncology & carcinogenesis ,medicine ,Cancer research ,Humans ,NODAL ,Gene ,Janus Kinases ,Signal Transduction ,030215 immunology - Published
- 2017
18. Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphoma
- Author
-
Paloma Martín, Mariano Provencio, Manuela Mollejo, David Pérez-Callejo, Lucia Pedrosa, José Gómez-Codina, Juan F. García, Javier Menárguez, Carmen Bárcena, Luis de la Cruz-Merino, Antonio Rueda, Sagrario Gómez, Margarita Sánchez-Beato, Ana Royuela, Francisca I. Camacho, Cristina Quero, Consuelo Parejo, Alberto J. Arribas, Delvys Rodriguez-Abreu, Julia González-Rincón, Luciano Cascione, Ivo Kwee, Francesco Bertoni, Marta Llanos, Silvia Monsalvo, Carmen Bellas, Santiago Montes-Moreno, Socorro María Rodríguez-Pinilla, Miriam Mendez, and Miguel A. Piris
- Subjects
Male ,B Cells ,Cell Lines ,Biopsy ,Follicular lymphoma ,medicine.disease_cause ,Hematologic Cancers and Related Disorders ,White Blood Cells ,Animal Cells ,Medicine and Health Sciences ,Copy-number variation ,Frameshift Mutation ,Lymphoma, Follicular ,B-Lymphocytes ,Mutation ,Multidisciplinary ,Massive parallel sequencing ,Cell Differentiation ,Hematology ,Genomics ,Diffuse large B-cell lymphoma ,Middle Aged ,Copy Number Variation ,Neoplasm Proteins ,Cell Transformation, Neoplastic ,Oncology ,Medicine ,Lymphomas ,Female ,Biological Cultures ,Lymphoma, Large B-Cell, Diffuse ,Cellular Types ,Raji Cells ,Research Article ,Adult ,Follicular Lymphoma ,Immune Cells ,Science ,Immunology ,Surgical and Invasive Medical Procedures ,Biology ,Research and Analysis Methods ,Genome Complexity ,Genetics ,medicine ,Humans ,Antibody-Producing Cells ,Aged ,Blood Cells ,Biology and Life Sciences ,Cancers and Neoplasms ,Computational Biology ,Cell Biology ,medicine.disease ,GNA13 ,Lymphoma ,Transformation (genetics) ,Cancer research ,Follow-Up Studies - Abstract
Follicular lymphoma (FL) is an indolent but largely incurable disease. Some patients suffer histological transformation to a more aggressive subtype with poorer prognosis. This study aimed to improve our understanding of the genetics underlying FL histological transformation, and to identify genetic drivers or promoters of the transformation by elucidating the differences between FL samples from patients who did and did not transform. We conducted targeted massive parallel sequencing of 22 pre-transformed FL/transformed diffuse large B-cell lymphoma pairs and 20 diagnostic samples from non-transformed FL patients. Additionally, 22 matched samples from 11 transformed FL patients (pre-transformed FL and diffuse large B-cell lymphoma) and 9 non-transformed FLs were studied for copy number variation using SNP arrays. We identified recurrently mutated genes that were enriched at transformation, most notably LRP1B, GNA13 and POU2AF1, which have roles in B-cell differentiation, GC architecture and migration. Mutations in POU2AF1 might be associated with lower levels of expression, were more frequent in transformed FLs, and seemed to be specific to transformed- compared with de novo-diffuse large B-cell lymphomas. Pre-transformed FLs carried more mutations per sample and had greater subclonal heterogeneity than non-transformed FLs. Finally, we identified four mutated genes in FL samples that differed between patients who did and did not transform: NOTCH2, DTX1, UBE2A and HIST1H1E. The presence of mutations in these genes was associated with shorter time to transformation when mutated in the FL biopsies. This information might be useful for identifying patients at higher risk of transformation.
- Published
- 2019
19. Lymphoplasmacytic lymphoma associated with diffuse large B-cell lymphoma: Progression or divergent evolution?
- Author
-
Magdalena Adrados, Macarena Boiza-Sánchez, Socorro María Rodríguez-Pinilla, Elham Askari, Rebeca Manso, Carlos Blas-López, Miguel Angel Limeres-González, Miguel A. Piris, Elena Aguirregoicoa-García, Rocío Salgado, Olga Balagué, Cristina Chamizo, Carlos Santonja, and Javier Menárguez
- Subjects
Male ,Pathology ,B Cells ,Lymphoma ,Physiology ,Molecular biology ,Gene Rearrangement, B-Lymphocyte, Heavy Chain ,Somatic evolution in cancer ,Lymphoplasmacytic Lymphoma ,Hematologic Cancers and Related Disorders ,White Blood Cells ,Sequencing techniques ,Animal Cells ,Bone Marrow ,immune system diseases ,Immune Physiology ,hemic and lymphatic diseases ,Medicine and Health Sciences ,Missense mutation ,DNA sequencing ,Aged, 80 and over ,Multidisciplinary ,Nonsense Mutation ,Hematology ,Genomics ,Middle Aged ,BCL6 ,Proto-Oncogene Proteins c-bcl-2 ,Oncology ,Disease Progression ,Proto-Oncogene Proteins c-bcl-6 ,Medicine ,Female ,Lymphoma, Large B-Cell, Diffuse ,Cellular Types ,Transcriptome Analysis ,Research Article ,Adult ,Next-Generation Sequencing ,medicine.medical_specialty ,Immune Cells ,Science ,Immunology ,Mutation, Missense ,Clonal Evolution ,Proto-Oncogene Proteins c-myc ,Genetic Heterogeneity ,Germline mutation ,Diagnostic Medicine ,Genetics ,Cancer Detection and Diagnosis ,medicine ,Humans ,Antibody-Producing Cells ,Aged ,Blood Cells ,business.industry ,Cancers and Neoplasms ,Biology and Life Sciences ,Computational Biology ,Cell Biology ,Gene rearrangement ,Genome Analysis ,medicine.disease ,Research and analysis methods ,Molecular biology techniques ,Immune System ,Myeloid Differentiation Factor 88 ,Mutation ,Somatic Mutation ,business ,Diffuse large B-cell lymphoma - Abstract
Aim Lymphoplasmacytic lymphoma (LPL) is an indolent mature B-cell-neoplasm with involvement of the bone marrow. At least 90% of LPLs carry MYD88-L265P mutation and some of them (~10%) transform into diffuse large B-cell-lymphoma (DLBCL). Material and methods Over the past 15 years we have collected 7 cases where the both LPL and DLBCL were diagnosed in the same patient. Clinical records, analytical data and histopathological specimens were reviewed. FISH studies on paraffin-embedded tissue for MYC, BCL2 and BCL6 genes were performed, as well as MYD88-L265P mutation and IGH rearrangement analysis by PCR. A mutational study was done by massive next generation sequencing (NGS). Results There were 4 women and 3 men between 36–91 years of age. Diagnoses were made simultaneously in 4 patients. In two cases the LPL appeared before the DLBCL and in the remaining case the high-grade component was discovered 5 years before the LPL. In 6 cases both samples shared the MYD88-L265P mutation. IGH rearrangement analysis showed overlapping features in two of 6 cases tested. Mutational study was evaluable in three cases for both samples showing shared and divergent mutations. Conclusions These data suggest different mechanisms of DLBCL development in LPL patients.
- Published
- 2020
20. Liquid Biopsy Is Useful to Identify the Genetic Profile of NHL-B at Diagnosis in Different Histological Subtypes
- Author
-
Diego Carbonell, Julia Suárez González, Solsireey Moreno, Javier Menárguez, José Luis Díez-Martín, María Chicano Lavilla, Carolina Martínez-Laperche, Mariana Bastos-Oreiro, Natalia Carolina Carrión, Francisco Diaz Crespo, Ismael Buño, Cristina Andres, and Gillen Oarbeascoa
- Subjects
Oncology ,medicine.medical_specialty ,medicine.diagnostic_test ,Immunology ,Follicular lymphoma ,Lymph node biopsy ,Cell Biology ,Hematology ,Biology ,medicine.disease ,BCL6 ,Biochemistry ,Lymphoma ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Mantle cell lymphoma ,Liquid biopsy ,Diffuse large B-cell lymphoma ,Plasmablastic lymphoma - Abstract
Introduction: Non-Hodgkin B lymphomas (NHL-B) are a large group of heterogeneous diseases, with well-defined, histological and clinical features. Currently, the lymph node biopsy is essential for diagnosis, often obtained from hard to reach areas. Our aims with this study was to analyze genetics variants at diagnosis trying to discriminate between different NHL-B histologic subtypes using formalin fixed paraffin embedded (FFPE) tissue sections and circulating tumor free DNA (ctDNA) samples. Material and Methods: This is a retrospective, cross-sectional, single-center study. Sixty patients were selected with a diagnosis of different NHL-B subtypes: Diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), marginal lymphoma (ML), mantle cell lymphoma (MCL) and plasmablastic lymphoma (PL). Sixty FFPE tissue samples and 23 ctDNA specimens obtained at diagnosis were selected. We performed an enrichment panel of 54 genes recurrently mutated in lymphomas (Lymphoma Solution; Sophia Genetics) by next generation sequencing (NGS; NextSeq; Illumina). The depth of 90% of the readings was greater than 2600x. Quantitative variables were expressed as median and range. Categorical variables were expressed as frequency and percentage. The Fisher exact test was used to compare the distribution of categorical variables. The Mann-Whitney test was used to compare differences between quantitative variables. Statistical significance was set at p < 0.05. Results: Our study shows that 97% (58/60) of patients presented any variant. The most frequently mutated genes were KMT2D, EP300 and SOCS1. Exclusive variants were detected in FL in the genes CCND1, PAX5, CREBBP, BCL2 and REL genes. In the same way, in DLCBL the variants detected in the BRAF, TCF3, XPO1, PIM1, CHD2, ID3 and BCL6 genes were exclusive of this subtype. Furthermore, the genes BCL2 (p=0.0021), CREBBP (p=0.0004), NOTCH2 (p=0.03), PAX5 (p=0.01) and TNFRSF14 (p=0.04) are more frequently altered in patients with FL, ATM (p=0.02) gene in MCL; NFKBIE (p=0.03), CIITA (p=0.02), MYC (p=0.009) and PIM1 (p=0.04) in DLCBL, among which it was found that high-grade lymphomas are more frequently associated with mutations in CHD2 (p=0.02), MYC (p=0.03) and MYD88 (p=0.02; data not shown). In the subgroup of 23 patients with paired samples (FFPE/ctDNA), 95% (22/23) of patients had mutations in any of the genes on the panel in FFPE tissue samples and 82% (19/23) in ctDNA specimens. The number of variants detected was different depending on the type of sample analysed, 52% of the variants were detected in both specimens, 39 only in FFPE tissue and 9% in ctDNA; Figure 1). In variants detected in both samples, the average value of the VAF was higher that when is detected only in one of the samples (FFPE: 28.1 vs 5.8 (p We did not find significant differences in the number of variants depending on the stage, classification, tumour burden or bulky mass (Table 1). Conclusion: In our study, we were able to identify genetic variables that could characterize different histological groups of NHL-B in FFPE tissue and ctDNA samples, by using a commercial gene panel of NGS. The mutational profile obtained from ctDNA and FFPE tissue is comparable in all histological subtypes, regardless tumour burden, aggressiveness or stage, throwing each one of them complemental information. These results support the hypothesis that could be possible to distinguish different histologies through non-invasive strategies, specially oriented to lesions where obtaining a tissue sample is difficult. We are working on the development of clinical-genetic algorithms that allow us to achieve our goal. Disclosures No relevant conflicts of interest to declare.
- Published
- 2019
21. Analysis of the mutational landscape of classic Hodgkin lymphoma identifies disease heterogeneity and potential therapeutic targets
- Author
-
Juan F. García, Beatriz Sanchez-Espiridion, Fernando Burgos, Mónica Estévez, Elena Mata, Javier Menárguez, Ana M. Martín-Moreno, Carlos Montalbán, Miguel A. Piris, Mariano Provencio, Ignacio Varela, Margarita Sánchez-Beato, Eva C. Diaz, Maria J Mestre, Antonio Díaz-López, Carlos Santonja, UAM. Departamento de Medicina, Universidad de Cantabria, Ministerio de Economía y Competitividad (España), Asociación Española Contra el Cáncer, Instituto de Salud Carlos III, and European Commission
- Subjects
0301 basic medicine ,Oncology ,medicine.medical_specialty ,Therapeutic target ,Medicina ,Disease ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,hemic and lymphatic diseases ,B-cell receptor ,medicine ,High prevalence ,business.industry ,Cancer ,Bcr signaling ,medicine.disease ,Mutational analysis ,humanities ,BCL10 ,Lymphoma ,030104 developmental biology ,BTK ,030220 oncology & carcinogenesis ,Hodgkin lymphoma ,business ,Research Paper - Abstract
Mata et al., Defining the mutational landscape of classic Hodgkin lymphoma is still a major research goal. New targeted next-generation sequencing (NGS) techniques may identify pathogenic mechanisms and new therapeutic opportunities related to this disease. We describe the mutational profile of a series of 57 cHL cases, enriched in Hodgkin and Reed-Sternberg (HRS) cells. Overall, the results confirm the presence of strong genomic heterogeneity. However, several variants were consistently detected in genes related to relevant signaling pathways, such as GM-CSF/IL-3, CBP/EP300, JAK/STAT, NF-kappaB, and numerous variants of genes affecting the B-cell receptor (BCR) pathway, such as BTK, CARD11, BCL10, among others. This unexpectedly high prevalence of mutations affecting the BCR pathway suggests some requirement for active BCR signaling for cHL cell viability. Additionally, incubation of a panel of cHL cellular models with selective BTK inhibitors in vitro constrains cell proliferation and causes cell death. Our results indicate new pathogenic mechanisms and therapeutic opportunities in this disease., This work was supported by grants from the Plan Nacional de I+D+I co-financed by the ISCIII-Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER), PI12/1832, RTICC RD06/0020/0107, PI14/00221, CIBER de Cancer, PIE15/0081 and PI16/01294, the Spanish Association for Cancer Research (AECC), and by funds of the U.T M.D. Anderson Cancer Center. MSB currently holds a Miguel Servet contract (CP11/00018 and CPII16/00024) from the ISCIII- MINECO-AES-FEDER (P.N.I+D+I 2008-2011), Spain.
- Published
- 2017
22. Evaluación sistemática de la biopsia de médula ósea en casos de sospecha de mielofibrosis primaria. Propuesta de informe diagnóstico estandarizado. Consenso de expertos de las SEAP/SEHH
- Author
-
Máximo Fraga, Carlos Besses, Santiago Montes-Moreno, Reyes Calzada, Javier Menárguez, Juan F. García, María Rozman, Agustín Acevedo, José María Raya, Antonio Ferrández, Mar Garcia, and Empar Mayordomo-Aranda
- Subjects
Gynecology ,medicine.medical_specialty ,Homogeneous ,business.industry ,medicine ,In patient ,medicine.disease ,business ,Myeloproliferative neoplasm ,Pathology and Forensic Medicine ,Surgery - Abstract
A consensus based on Delphi methodology was developed to produce a guide for the evaluation and reporting of bone marrow biopsies in patients with a clinical suspicion of myeloproliferative neoplasm with fibrosis. Ten expert haematopathologists formulated a questionnaire including: clinical and laboratory data required before regarding a biopsy suspicious for primary myelofibrosis (PMF), descriptive aspects to be reported and the main histopathological differential diagnoses to be considered. It was circulated among 37 hematopathologists and consensus was defined when more than 70% of the experts "strongly agreed" or "agreed" after two rounds. The recommendations gave rise to a proposal for a standardized diagnostic report form to aid in the diagnostic workup and homogeneous reporting of cases with a clinical suspicion of PMF.
- Published
- 2014
23. C-MYC is related to GATA3 expression and associated with poor prognosis in nodal peripheral T-cell lymphomas
- Author
-
Carmen Bellas, Paloma Martín-Acosta, Pilar Llamas, Federico Rojo, Manuela Mollejo, Rebeca Manso, Miguel A. Piris, Javier Menárguez, and Socorro María Rodríguez-Pinilla
- Subjects
0301 basic medicine ,PTCL ,Poor prognosis ,Biopsy ,T cell ,GATA3 Transcription Factor ,Bioinformatics ,Proto-Oncogene Proteins c-myc ,03 medical and health sciences ,0302 clinical medicine ,GATA3 ,C-MYC ,Medicine ,Online Only Articles ,Survival analysis ,business.industry ,Lymphoma, T-Cell, Peripheral ,Hematology ,Prognosis ,Survival Analysis ,Ki-67 Antigen ,030104 developmental biology ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Cancer research ,business ,NODAL - Abstract
Funding: this study was supported by grants from the Asociacion Espanola contra el Cancer (AECC), Ministerio de Economia y Competitividad (MINECO) (SAF2013-47416-R), Instituto Salud Carlos III (ISCIII) – Fondos de Investigacion Sanitaria (RD06/0020/0107, RD012/0036/0060 and FIS11/1759). The Instituto de Investigacion Marques de Valdecilla (IDIVAL) is partly funded by the Sociedad para el Desarrollo Regional de Cantabria (SODERCAN)
- Published
- 2016
24. Autochthonous Crimean-Congo Hemorrhagic Fever in Spain
- Author
-
Anabel, Negredo, Fernando, de la Calle-Prieto, Eduardo, Palencia-Herrejón, Marta, Mora-Rillo, Jenaro, Astray-Mochales, María P, Sánchez-Seco, Esther, Bermejo Lopez, Javier, Menárguez, Ana, Fernández-Cruz, Beatriz, Sánchez-Artola, Elena, Keough-Delgado, Eva, Ramírez de Arellano, Fátima, Lasala, Jakob, Milla, Jose L, Fraile, Maria, Ordobás Gavín, Amalia, Martinez de la Gándara, Lorenzo, López Perez, Domingo, Diaz-Diaz, M Aurora, López-García, Pilar, Delgado-Jimenez, Alejandro, Martín-Quirós, Elena, Trigo, Juan C, Figueira, Jesús, Manzanares, Elena, Rodriguez-Baena, Luis, Garcia-Comas, Olaia, Rodríguez-Fraga, Nicolás, García-Arenzana, Maria V, Fernández-Díaz, Victor M, Cornejo, Petra, Emmerich, Jonas, Schmidt-Chanasit, Jose R, Arribas, Fernando, Cava, European Union, and Red de Investigación Cooperativa en Enfermedades Tropicales (España)
- Subjects
0301 basic medicine ,Crimean–Congo hemorrhagic fever ,Male ,Infectious Disease Transmission, Patient-to-Professional ,Colon ,Tick ,Polymerase Chain Reaction ,Virus ,03 medical and health sciences ,Necrosis ,Fatal Outcome ,parasitic diseases ,medicine ,media_common.cataloged_instance ,Humans ,Viral rna ,European union ,media_common ,biology ,business.industry ,Infectious disease transmission ,General Medicine ,Middle Aged ,biology.organism_classification ,medicine.disease ,Virology ,030104 developmental biology ,Liver ,Spain ,Hemorrhagic Fever Virus, Crimean-Congo ,Female ,Hemorrhagic Fever, Crimean ,Contact Tracing ,business ,Liver pathology ,Multiplex Polymerase Chain Reaction ,Contact tracing - Abstract
Crimean-Congo hemorrhagic fever (CCHF) is a widely distributed, viral, tickborne disease. In Europe, cases have been reported only in the southeastern part of the continent. We report two autochthonous cases in Spain. The index patient acquired the disease through a tick bite in the province of Ávila - 300 km away from the province of Cáceres, where viral RNA from ticks was amplified in 2010. The second patient was a nurse who became infected while caring for the index patient. Both were infected with the African 3 lineage of this virus. (Funded by Red de Investigación Cooperativa en Enfermedades Tropicales [RICET] and Efficient Response to Highly Dangerous and Emerging Pathogens at EU [European Union] Level [EMERGE].). Supported by Red de Investigación Cooperativa en Enferme-dades Tropicales (RICET grant, RD12/0018/0023) and EMERGE (Efficient Response to Highly Dangerous and Emerging Patho-gens at EU [European Union] Level), a joint action funded under the third EU Health Program (677066),.Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.We thank Julio Farias of the Pathology Department at Gregorio Marañón University General Hospital and Maria José Buitrago and the rest of the members of the Grupo de Respuesta Rápida of the Centro Nacional de Microbiología for their help. Sí
- Published
- 2017
25. PB1826 COMPOSITE LYMPHOMA CONTAINING MANTLE CELL AND PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED: A REPORT OF 2 CASES TREATED WITH UP-FRONT AUTOLOGOUS STEM CELL TRANSPLANTATION
- Author
-
Javier Menárguez, A. Burdaspal, I. González-Gascón Y Marín, Maria‐Stefania Infante, Carolina Martínez-Laperche, José Luis Díez-Martín, J.A. Hernández Rivas, Mi Kwon, and Yolanda Castro
- Subjects
Pathology ,medicine.medical_specialty ,medicine.anatomical_structure ,Autologous stem-cell transplantation ,business.industry ,Cell ,Composite lymphoma ,medicine ,Peripheral T-cell lymphoma not otherwise specified ,Hematology ,Mantle (mollusc) ,medicine.disease ,business - Published
- 2019
26. p-MAPK1 expression associated with poor prognosis in angioimmunoblastic T-cell lymphoma patients
- Author
-
Javier Menárguez, Pilar Llamas, Miguel A. Piris, Rebeca Manso, Mónica García-Cosío, Santiago Montes-Moreno, Nerea Carvajal, Federico Rojo, Manuela Mollejo, Socorro María Rodríguez-Pinilla, Giovanna Roncador, and M. Ángeles Pérez-Sáenz
- Subjects
0301 basic medicine ,Mitogen-Activated Protein Kinase 1 ,Poor prognosis ,Angioimmunoblastic T-cell lymphoma ,business.industry ,Hematology ,Kaplan-Meier Estimate ,medicine.disease ,Lymphoma, T-Cell ,Prognosis ,Immunohistochemistry ,Gene Expression Regulation, Neoplastic ,03 medical and health sciences ,030104 developmental biology ,Immunoblastic Lymphadenopathy ,Cancer research ,Biomarkers, Tumor ,Medicine ,Humans ,Phosphorylation ,MAPK1 ,business - Published
- 2016
27. The presence of genomic imbalances is associated with poor outcome in patients with burkitt lymphoma treated with dose-intensive chemotherapy including rituximab
- Author
-
C. Olivier, Rocío Benito, Eva Lumbreras, Juan Luis García, Josep-Maria Ribera, Carlos Grande, Luis A. Corchete-Sánchez, Alfonso García de Coca, Jesus M Hernández-Sánchez, Maribel Forero-Castro, Jordi Ribera, Pere Barba, Estrella Carrillo, María Hernández-Sánchez, Lourdes Escoda, Cristina Robledo, Javier Menárguez, Jesús M. Hernández-Rivas, Mar Tormo, Fundación Castellano Leonesa de Hematología y Hemoterapia, Junta de Castilla y León, Red Temática de Investigación Cooperativa en Cáncer (España), European Commission, Sociedad Española de Hematología y Hemoterapia, Instituto de Salud Carlos III, Ministerio de Economía y Competitividad (España), and Universidad Pedagógica y Tecnológica de Colombia
- Subjects
Oncology ,Male ,medicine.medical_treatment ,array-based comparative genomic hybridization (aCGH) ,Intensive chemotherapy ,Kaplan-Meier Estimate ,Bioinformatics ,0302 clinical medicine ,rituximab ,Antineoplastic Combined Chemotherapy Protocols ,Young adult ,Comparative Genomic Hybridization ,Genome ,Array-based comparative genomic hybridization ,Burkitt lymphoma ,High-Throughput Nucleotide Sequencing ,Hematology ,Middle Aged ,Prognosis ,Burkitt Lymphoma ,humanities ,3. Good health ,Treatment Outcome ,030220 oncology & carcinogenesis ,outcome ,Rituximab ,Female ,medicine.drug ,Adult ,medicine.medical_specialty ,Adolescent ,education ,Biology ,Next-generation sequencing, outcome ,03 medical and health sciences ,Young Adult ,Internal medicine ,medicine ,Humans ,In patient ,Aged ,Chromosome Aberrations ,Chemotherapy ,medicine.disease ,GNA13 ,Lymphoma ,stomatognathic diseases ,next-generation sequencing ,030215 immunology ,Comparative genomic hybridization - Abstract
Part of this study has been reported as an oral presentation at the EHA Meeting in Vienna 2015., The introduction of Rituximab has improved the outcome and survival rates of Burkitt lymphoma (BL). However, early relapse and refractoriness are current limitations of BL treatment and new biological factors affecting the outcome of these patients have not been explored. This study aimed to identify the presence of genomic changes that could predict the response to new therapies in BL. Forty adolescent and adult BL patients treated with the Dose-Intensive Chemotherapy Including Rituximab (Burkimab) protocol (Spanish Programme for the Study and Treatment of Haematological Malignancies; PETHEMA) were analysed using array-based comparative genomic hybridization (CGH). In addition, the presence of TP53, TCF3 (E2A), ID3 and GNA13 mutations was assessed by next-generation sequencing (NGS). Ninety-seven per cent of the patients harboured genomic imbalances. Losses on 11q, 13q, 15q or 17p were associated with a poor response to Burkimab therapy (P = 0·038), shorter progression-free survival (PFS; P = 0·007) and overall survival (OS; P = 0·009). The integrative analysis of array-CGH and NGS showed that 26·3% (5/19) and 36·8% (7/19) of patients carried alterations in the TP53 and TCF3 genes, respectively. TP53 alterations were associated with shorter PFS (P = 0·011) while TCF3 alterations were associated with shorter OS (P = 0·032). Genetic studies could be used for risk stratification of BL patients treated with the Burkimab protocol., This work was supported in part by: grant no 306242-NGS-PTL from European Union’s Seventh Framework Programme (FP7/2007-2013), Fundacion-Castellano-Leonesa de Hematologia-y-Hemoterapia (FUCALHH 2013), Consejeria de Educacion, Junta de Castilla y León (HUS272U13), SACYL research projects: GRS1172/A/15, GRS 994/A/14, BIO/SA10/14, BIO/SA31/13. Fondo de Investigaciones Sanitarias FISPI09/01543, FIS-PI12/00281, PI14/01971, COST-ActionEuGESMA (BM0801), Fundacion Española de Hematologia y Hemoterapia (FEHH), and by grants RD12/0036/0069, RD12/ 0036/0029 and RD12/0036/0044 from the Red Tematica de Investigacion Cooperativa en Cancer (RTICC), Instituto de Salud Carlos III (ISCIII), the Spanish Ministry of Economy and Competitiveness and the European Regional Development Fund (ERDF) ‘Una manera de hacer Europa’ (Innocampus). NGS was performed as part of the IRON-II collaborative network of haematological laboratories. MFC was supported by study commission no 223-2011 granted by the UPTC, Colombia. MHS was supported by Junta de Castilla y Leon from the ERDF.
- Published
- 2015
28. Recomendaciones de GESIDA/PETHEMA sobre el diagnóstico y tratamiento de los linfomas en pacientes infectados por el virus de la inmunodeficiencia humana
- Author
-
Pilar Miralles, José Tomás Navarro, Juan Berenguer, José Gómez Codina, Mi Kwon, David Serrano, José Luis Díez-Martín, Salvador Villà, Rafael Rubio, Javier Menárguez, and José-María Ribera Santasusana
- Subjects
0301 basic medicine ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,030220 oncology & carcinogenesis ,General Medicine - Published
- 2018
29. GESIDA/PETHEMA recommendations on the diagnosis and treatment of lymphomas in patients infected by the human immunodeficiency virus
- Author
-
Pilar Miralles, José Gomez Codina, Rafael Rubio, David P. Serrano, José-María Ribera Santasusana, Juan Berenguer, José-Tomás Navarro, Mi Kwon, Salvador Villà, José Luis Díez-Martín, and Javier Menárguez
- Subjects
medicine.medical_specialty ,Anti-HIV Agents ,medicine.medical_treatment ,Population ,HIV Infections ,03 medical and health sciences ,0302 clinical medicine ,Acquired immunodeficiency syndrome (AIDS) ,immune system diseases ,hemic and lymphatic diseases ,Internal medicine ,Humans ,Medicine ,EPOCH (chemotherapy) ,education ,education.field_of_study ,business.industry ,Lymphoma, Non-Hodgkin ,virus diseases ,Prognosis ,medicine.disease ,Hodgkin's lymphoma ,Combined Modality Therapy ,Hodgkin Disease ,Lymphoma ,Non-Hodgkin's lymphoma ,Stanford V ,030220 oncology & carcinogenesis ,business ,ESHAP ,030215 immunology - Abstract
The incidence of non-Hodgkin's lymphoma and Hodgkin's lymphoma is higher in patients with HIV infection than in the general population. Following the introduction of combination antiretroviral therapy (cART), the prognostic significance of HIV-related variables has decreased, and lymphoma-related factors have become more pronounced. Currently, treatments for lymphomas in HIV-infected patients do not differ from those used in the general population. However, differentiating characteristics of seropositive patients, such as the need for cART and specific prophylaxis and treatment of certain opportunistic infections, should be considered. This document updates recommendations on the diagnosis and treatment of lymphomas in HIV infected patients published by GESIDA/PETHEMA in 2008.
- Published
- 2018
30. Chronic lymphocytic leukemia cells in lymph nodes show frequent NOTCH1 activation
- Author
-
José A. García-Marco, Javier Alves, Marina Pollán, Sagrario Gómez, Margarita Sánchez-Beato, Miguel A. Piris, Santiago Montes-Moreno, Arantza Onaindia, Manuela Mollejo, Juan F. García, Paloma Martín-Acosta, Ana Batlle, Miguel Piris-Villaespesa, Javier Menárguez, Carolina Martínez-Laperche, Julia González-Rincón, Laura Cereceda, Máximo Fraga, Socorro María Rodríguez-Pinilla, Sonia de González Villambrosia, Universidad de Cantabria, Ministerio de Economía y Competitividad (España), Instituto de Salud Carlos III, and Asociación Española Contra el Cáncer
- Subjects
Transcriptional Activation ,Chronic lymphocytic leukemia ,medicine.disease_cause ,NOTCH1 activation ,Antigen ,Mutation Rate ,hemic and lymphatic diseases ,medicine ,Humans ,Epigenetics ,Receptor, Notch1 ,Online Only Articles ,CD20 ,Mutation ,biology ,Hematology ,Ribonucleoprotein, U2 Small Nuclear ,medicine.disease ,Phosphoproteins ,Prognosis ,Leukemia, Lymphocytic, Chronic, B-Cell ,Leukemia ,Immunology ,biology.protein ,Cancer research ,chronic lymphocytic leukemia ,Lymph ,Lymph Nodes ,RNA Splicing Factors - Abstract
Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in the Western world. Pathogenic mechanisms involve multiple external events (such as microenvironmental and antigenic stimuli) and internal events (genetic and epigenetic alterations) that are associated with the transformation, progression and evolution of CLL. CLL is characterized by an accumulation of mature B cells in peripheral blood, bone marrow and lymphoid tissues. Extracellular stimuli play an important role in the development and maintenance of neoplastic cells. B-CLL cells proliferate and activate pathogenic signaling pathways in anatomical structures known as proliferation centers, which are usually more conspicuous in involved lymph nodes.1 Its clinical course is quite heterogeneous, whereby some patients progress rapidly and have short survival, whereas others have a more stable clinical course that may not need treatment for years. This work was supported by grants from the Ministerio de Economía y Competitividad (MINECO) (SAF2013-47416-R) Instituto de Salud Carlos III (ISCIII)- FEDER – MINECO- AES (CP11/00018, PI10/00621, RD012/0036/0060), and Asociación Española contra el Cancer (AECC). MS-B is supported by a Miguel Servet contract from ISCIII-FEDER (CP11/00018). Salary support to SG is provided by CP11/00018, from ISCIII-FEDER. JG-R is supported by a predoctoral grant from the Fundación Investigación Puerta de Hierro. Sí
- Published
- 2015
31. PIM Kinases as Potential Therapeutic Targets in a Subset of Peripheral T Cell Lymphoma Cases
- Author
-
Ana María García Collazo, Manuela Mollejo, Francisco X. Real, Socorro María Rodríguez-Pinilla, James R. Bischoff, Carmen Almaraz, Rebeca Madureira, Giovanna Roncador, Javier Menárguez, Juan F. García, Esther González Cantalapiedra, Miguel A. Piris, Esperanza Martín-Sánchez, Lina Odqvist, Helena Pisonero, Beatriz Dominguez-Gonzalez, Margarita Sánchez-Beato, Carmen Blanco-Aparicio, Joaquín Pastor Fernández, Pablo L. Ortiz-Romero, José Luis Rodríguez-Peralto, F. Javier Alves, Fernando González-Palacios, and Soraya Curiel del Olmo
- Subjects
Cell signaling ,Cell cycle checkpoint ,Cancer Treatment ,lcsh:Medicine ,Apoptosis ,Signal transduction ,Pathology and Laboratory Medicine ,hemic and lymphatic diseases ,Molecular Cell Biology ,Basic Cancer Research ,Drug Discovery ,Medicine and Health Sciences ,Phosphorylation ,RNA, Small Interfering ,lcsh:Science ,Anaplastic large-cell lymphoma ,Chemotherapeutic Agents ,Multidisciplinary ,Cancer Drug Discovery ,Cell Death ,Kinase ,Cell Cycle ,Drug Synergism ,Cell cycle ,Proto-Oncogene Proteins c-pim-1 ,Signal inhibition ,STAT signaling ,medicine.anatomical_structure ,Cèl·lules -- Interacció ,Oncology ,Cell Processes ,Oncology Agents ,Anti-apoptotic signaling ,Transcriptome Analysis ,Molecular Pathology ,Research Article ,Cell biology ,Drug Research and Development ,Cell Survival ,T cell ,Antineoplastic Agents ,Biology ,Oncogenic signaling ,Cell Line, Tumor ,medicine ,Humans ,Molecular Biology ,Cell Proliferation ,Pharmacology ,Biology and life sciences ,lcsh:R ,Transducció de senyal cel·lular ,Computational Biology ,Lymphoma, T-Cell, Peripheral ,medicine.disease ,Genome Analysis ,Cell culture ,Immunology ,Cancer research ,lcsh:Q ,Cisplatin ,Genome Expression Analysis ,Cytometry - Abstract
Currently, there is no efficient therapy for patients with peripheral T cell lymphoma (PTCL). The Proviral Integration site of Moloney murine leukemia virus (PIM) kinases are important mediators of cell survival. We aimed to determine the therapeutic value of PIM kinases because they are overexpressed in PTCL patients, T cell lines and primary tumoral T cells. PIM kinases were inhibited genetically (using small interfering and short hairpin RNAs) and pharmacologically (mainly with the pan-PIM inhibitor (PIMi) ETP-39010) in a panel of 8 PTCL cell lines. Effects on cell viability, apoptosis, cell cycle, key proteins and gene expression were evaluated. Individual inhibition of each of the PIM genes did not affect PTCL cell survival, partially because of a compensatory mechanism among the three PIM genes. In contrast, pharmacological inhibition of all PIM kinases strongly induced apoptosis in all PTCL cell lines, without cell cycle arrest, in part through the induction of DNA damage. Therefore, pan-PIMi synergized with Cisplatin. Importantly, pharmacological inhibition of PIM reduced primary tumoral T cell viability without affecting normal T cells ex vivo. Since anaplastic large cell lymphoma (ALK+ ALCL) cell lines were the most sensitive to the pan-PIMi, we tested the simultaneous inhibition of ALK and PIM kinases and found a strong synergistic effect in ALK+ ALCL cell lines. Our findings suggest that PIM kinase inhibition could be of therapeutic value in a subset of PTCL, especially when combined with ALK inhibitors, and might be clinically beneficial in ALK+ ALCL. This work was supported by grants from the Asociación Española Contra el Cáncer, Fondo de Investigaciones Sanitarias (PI051623, PI052800 and FIS11/1759), RTICC (RD06/0020/0107) and Ministerio de Ciencia e Innovación (SAF2008-0387-1). EMS was supported by a grant from the Department of Education, Universities and Research of the Basque Government (BFI08.207). MSB was supported by a Contract Miguel Servet from Fondo de Investigaciones Sanitarias (CP11/00018).
- Published
- 2014
32. Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma
- Author
-
Fabian Frontzek, Annette M. Staiger, Myroslav Zapukhlyak, Wendan Xu, Irina Bonzheim, Vanessa Borgmann, Philip Sander, Maria Joao Baptista, Jan-Niklas Heming, Philipp Berning, Ramona Wullenkord, Tabea Erdmann, Mathias Lutz, Pia Veratti, Sophia Ehrenfeld, Kirsty Wienand, Heike Horn, John R. Goodlad, Matthew R. Wilson, Ioannis Anagnostopoulos, Mario Lamping, Eva Gonzalez-Barca, Fina Climent, Antonio Salar, Josep Castellvi, Pau Abrisqueta, Javier Menarguez, Teresa Aldamiz, Julia Richter, Wolfram Klapper, Alexandar Tzankov, Stefan Dirnhofer, Andreas Rosenwald, José Luis Mate, Gustavo Tapia, Peter Lenz, Cornelius Miething, Wolfgang Hartmann, Björn Chapuy, Falko Fend, German Ott, José-Tomas Navarro, Michael Grau, and Georg Lenz
- Subjects
Science - Abstract
Plasmablastic lymphoma (PBL) is an aggressive lymphoma subtype characterized by poor prognosis but the molecular knowledge of the disease is limited. Here, the authors perform whole exome sequencing and copy number determination of primary samples highlighting IRF4 and JAK-STAT pathways as therapeutic targets for PBL.
- Published
- 2021
- Full Text
- View/download PDF
33. Analysis of the Genomic Heterogeneity in Hodgkin Lymphoma Using Next Generation Sequencing
- Author
-
Maria J Mestre, Ana M. Martín-Moreno, Carlos Montalbán, Antonio Díaz-López, Fernando Burgos, Juan F. García, Javier Menárguez, Elena Mata, Miguel A. Piris, and Carlos Santonja
- Subjects
Sanger sequencing ,Genetics ,Mutation ,Massive parallel sequencing ,Immunology ,breakpoint cluster region ,Cell Biology ,Hematology ,Gene mutation ,Biology ,medicine.disease_cause ,medicine.disease ,Biochemistry ,symbols.namesake ,Reed–Sternberg cell ,medicine ,symbols ,Mantle cell lymphoma ,Diffuse large B-cell lymphoma - Abstract
Classical Hodgkin´s lymphoma (cHL) is a clonal proliferation of the characteristic Hodgkin and Reed Sternberg cells (HRS), diluted in a reactive inflammatory background, and characterized by a defective B cell immunophenotype. Few studies have been aimed to the identification of the driver mutations in this disease, and only occasional gene mutations in members of the NF-kappaB and JAK/STAT pathways, and, more recently B2M, have been previously described. We analyzed 57 cHL tumor samples (FFPE) using massive parallel sequencing (Ion Torrent™ semiconductor technology). To increase coverage a previous tumor cell enrichment process by punch tissue cores from selected tumor-rich areas was implemented. In addition, we sequenced 7 cHL cell lines using the same technical approach. Bioinformatics analysis, including alignment with germline sequences and SNPs filtering, were done using the Torrent Suite Software and Variant Caller. Pathogenic prediction of single nucleotide variants (SNVs) and mutation interpretation were performed using the Alamut and Provean softwares. All experiments were done in duplicate to minimize false positive rates. Overall, the results show very high genomic heterogeneity with a range of 10-400 SNVs per sample, most of them (~60%) missense type. We found a relatively large number of genes recurrently mutated at low frequency and only a few genes mutated in up to 15-20% of the patients, reflecting a high level of genomic instability in the neoplasm. Specific mutations in genes previously described in cHL (NFKBIA, TNFRSF14) and in diffuse large B-cell lymphomas (CARD11, STAT6, CREBBP, CMYB) were consistently found, as well as new SNVs in genes not previously described (BTK, NFKB2). Mutations affecting selected genes (B2M, CARD11, NFKBIA, CSF2RB, and STAT3) in cell lines were additionally validated by Sanger sequencing. Of note, we found high prevalence of mutations affecting BTK and the BCR pathway, suggesting some dependencies of active BCR signaling albeit the absence of BCR expression by HRS cells. Consistent with this interpretation, incubationof a panel of cHL cellular models with either Ibrutininb or AVL-292, selective-BTK inhibitors, in vitro constrains cell proliferation and causes cell death. Interestingly, the concentration to induce cell apoptosis in cHL was comparable to other cell models of diffuse large B-cell and mantle cell lymphoma sustaining the requirement of an active BCR signaling for cHL cell viability. In conclusion, cHL is characterized by high genomic instability, including numerous mutations in genes related with B-cell function and specific signaling pathways. Pathogenic predictions of the different SNVs identify potential driver mutations that can be associated with the pathogenesis of the disease and might represent new therapeutic targets. Disclosures No relevant conflicts of interest to declare.
- Published
- 2015
34. Chronic lymphocytic leukemia cells in lymph nodes show frequent NOTCH1 activation
- Author
-
Arantza Onaindia, Sagrario Gómez, Miguel Piris-Villaespesa, Carolina Martínez-Laperche, Laura Cereceda, Santiago Montes-Moreno, Ana Batlle, Sonia González de Villambrosia, Marina Pollán, Paloma Martín-Acosta, Julia González-Rincón, Javier Menarguez, Javier Alvés, Socorro M. Rodriguez-Pinilla, Juan F. García, Manuela Mollejo, Máximo Fraga, José A. García-Marco, Miguel A. Piris, and Margarita Sánchez-Beato
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.